-
Mashup Score: 0
Background Evaluating the effects of cancer diagnosis and treatment on a patient’s overall well-being is crucial and health-related quality of life (HRQoL) is a reliable metric for assessing this impact. Little is known about HRQoL among cancer survivors across various stages and treatments. The study examined individual and clinical factors influencing HRQoL among cancer survivors. Methods A cross-sectional study was conducted in two specialised cancer care hospitals in Dhaka, Bangladesh. Cancer-diagnosed adults receiving treatment at selected hospitals from January to May 2022 were enrolled. The 5-level EuroQol-5 Dimensions version (EQ-5D-5L) instrument was used to collect HRQoL data. HRQoL scores were derived using UK value sets. The investigation used a multivariable Tobit regression model to determine the association between independent variables and HRQoL scores. Results A total of 607 adult patients were enrolled, with 55% being females and 66% aged 36 to 64 years. Reported heal
Source: bmccancer.biomedcentral.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 2Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study) - BMC Cancer - 6 month(s) ago
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a painful, dose-limiting adverse effect of commonly used chemotherapeutic agents. The purpose of this exploratory study was to evaluate the efficacy and safety of mirogabalin in patients with moderate to severe CIPN during chemotherapy and the effects of 12 weeks’ intervention on chemotherapy completion and CIPN severity. Methods Patients experiencing moderate to severe CIPN while undergoing oxaliplatin- or taxane-containing chemotherapy for colorectal, gastric, non-small-cell lung, or breast cancer received mirogabalin at between 5 and 15 mg twice daily. The primary endpoint was change in numeric rating scale (NRS) score for pain from baseline to week 12. Secondary endpoints included NRS scores for tingling and sleep, completion of chemotherapy, severity of CIPN, and quality of life (QOL) scores. The safety endpoint was incidence of adverse events. Results Of 58 patients who consented to participation, 52 were eligible an
Source: bmccancer.biomedcentral.comCategories: General Medicine News, General HCPsTweet-
Intervention with mirogabalin during chemotherapy may be effective and safe for cancer patients with moderate to severe chemotherapy-induced peripheral neuropathy, finds a study published in #BMCCancer https://t.co/x8dv1oScL2
-
-
Mashup Score: 2
Background Aponermin, a circularly permuted tumor necrosis factor-related apoptosis-inducing ligand, is a potential death receptor 4/5-targeted antitumour candidate. Previous phase 1/2 studies have demonstrated the efficacy of aponermin in patients with relapsed or refractory multiple myeloma (RRMM). To confirm the superiority of aponermin plus thalidomide and dexamethasone (aponermin group) over placebo plus thalidomide and dexamethasone (placebo group) in RRMM, a randomized, double-blinded, placebo controlled phase 3 trial was performed. Methods Four hundred seventeen patients with RRMM who had previously received at least two regimens were randomly assigned (2:1) to receive aponermin, thalidomide, and dexamethasone or placebo, thalidomide, and dexamethasone. The primary endpoint was progression-free survival (PFS). Key secondary endpoints included overall survival (OS) and overall response rate (ORR). Results A total of 415 patients received at least one dose of trial treatment (276
Source: bmccancer.biomedcentral.comCategories: Latest Headlines, Partners & KOLsTweet-
It speaks to the global inequities in cancer care/access that a trial with a thalidomide-dex doublet as a control arm for relapsed/refractory myeloma is published in 2023. Realities for most patients in the world very different. 🤯💔 https://t.co/wOJBeQ9Rtf #mmsm https://t.co/ixkIWhB0d4 https://t.co/Xv8v0OwakG
-
-
Mashup Score: 2Association of meat consumption with the risk of gastrointestinal cancers: a systematic review and meta-analysis - BMC Cancer - 7 month(s) ago
Background The association between gastrointestinal cancer and types of meat consumption, including red meat, processed meat, or a combination of both, remains disputable. Therefore, we performed a systematic review and meta-analysis of prospective cohort studies to estimate the association between meat consumption and gastrointestinal cancer risk. Methods PubMed, EmBase, and the Cochrane library databases were searched systematically for eligible studies that investigated the relation between meat consumption and the risk of developing gastrointestinal cancers, including esophageal cancer (EC), gastric cancer (GC), colorectal cancer (CRC), colon cancer (CC), rectal cancer (RC), pancreatic cancer (PC), and hepatocellular carcinoma (HCC) throughout February, 2023. The pooled relative risk (RR) with 95% confidence interval (CI) was assigned as an effect estimate and calculated using a random-effects model with inverse variance weighting. Results Forty cohorts comprising 3,780,590 individ
Source: bmccancer.biomedcentral.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
A systematic review and meta-analysis published in #BMCCancer finds that higher meat consumption is associated with an increased risk of gastrointestinal cancers irrespective of whether it was red, processed, or total red and processed meat. https://t.co/9aaxbpRq4N
-
-
Mashup Score: 0Association of meat consumption with the risk of gastrointestinal cancers: a systematic review and meta-analysis - BMC Cancer - 9 month(s) ago
Background The association between gastrointestinal cancer and types of meat consumption, including red meat, processed meat, or a combination of both, remains disputable. Therefore, we performed a systematic review and meta-analysis of prospective cohort studies to estimate the association between meat consumption and gastrointestinal cancer risk. Methods PubMed, EmBase, and the Cochrane library databases were searched systematically for eligible studies that investigated the relation between meat consumption and the risk of developing gastrointestinal cancers, including esophageal cancer (EC), gastric cancer (GC), colorectal cancer (CRC), colon cancer (CC), rectal cancer (RC), pancreatic cancer (PC), and hepatocellular carcinoma (HCC) throughout February, 2023. The pooled relative risk (RR) with 95% confidence interval (CI) was assigned as an effect estimate and calculated using a random-effects model with inverse variance weighting. Results Forty cohorts comprising 3,780,590 individ
Source: bmccancer.biomedcentral.comCategories: Latest Headlines, Partners & KOLsTweet-
Association of meat consumption with the risk of gastrointestinal cancers: a systematic review and meta-analysis | BMC Cancer | Full Text https://t.co/wJukI0bjAJ
-
-
Mashup Score: 0
Background Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as monotherapy and combination therapy across several indications, both among newly-diagnosed and refractory patients with multiple myeloma (MM). However, there is limited evidence on treatment patterns and effectiveness of daratumumab in the real-world setting, particularly in first line (1 L). This study aimed to describe real-world treatment patterns and clinical outcomes among patients initiating daratumumab across different lines of therapy. Methods A retrospective chart review of adult patients with MM initiating daratumumab between November 2015 and March 2021 was conducted at two clinical sites in the United States. De-identified patient-level data were abstracted in an electronic case report form. Patient characteristics and treatment patterns were described. Clinical outcomes including overall response rate (ORR), progression-free survival, and time to next line of therapy were reported using descri
Source: bmccancer.biomedcentral.comCategories: Latest Headlines, Partners & KOLsTweet-
Reference 27 is a two center US study receiving dara from 2015- early 2021. https://t.co/y5jcyiyEFH This included patients in newly diagnosed MM, but even in those with 3+ lines of therapy, dara based combos more common than dara monotherapy. https://t.co/sf3KF13uOa
-
A study conducted in Bangladesh and published in #BMCCancer highlights the significant influence of cancer stage and site on survivors' overall health-related quality of life. https://t.co/9MNuMtjcwL